The Ensign ((ENSG)) has held its Q1 earnings call. Read on for the main highlights of the call.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The tone of Ensign’s latest earnings call was decidedly upbeat, with management stressing record occupancy, double‑digit growth in revenue and earnings, and another raise to full‑year guidance. Risks were framed as manageable and mostly tied to future transitions, such as new systems and turnaround deals, rather than any cracks in current performance.
Record Occupancy and Census Momentum
Ensign highlighted record occupancy levels, underscoring solid demand across its post‑acute portfolio and a strong start to the year. Same‑store occupancy reached 84.3% and transitioning facilities hit 85.1%, while managed care and Medicare census climbed sequentially by 6.2% and 8.3%, signaling ongoing volume and mix momentum.
Improved Skilled Mix and Medicare Revenue
The company continued to push its mix toward higher‑acuity, better‑paying patients, which is central to its earnings story. Skilled revenue grew 9.6% and skilled days 5.1% year over year, while Medicare revenue advanced roughly 9%–10% across same‑store and transitioning operations, boosting top‑line quality as well as quantity.
Strong Financial Results in Q1 FY2026
Financially, Q1 was a standout, with GAAP diluted EPS rising 21.9% to $1.67 and adjusted EPS up 21.7% to $1.85. Consolidated revenue increased 18.4% to $1.4 billion, while GAAP net income jumped 24.2% to $99.7 million and adjusted net income climbed 23.9% to $110.2 million, underscoring broad‑based operating leverage.
Raised Full‑Year Outlook
On the back of that strength, Ensign nudged its 2026 earnings range higher to $7.48–$7.62 per diluted share and lifted revenue guidance to $5.81–$5.86 billion. At the midpoint, management now expects roughly 15% earnings growth versus 2025 and 37% versus 2024, reinforcing a multi‑year growth narrative rather than a one‑off spike.
Robust M&A and Portfolio Expansion
M&A remains a key growth engine, with 22 operations and 21 real estate assets added in the quarter and nearly 100 facilities acquired or transitioned since 2024. The company brought in 2,662 skilled nursing beds and additional senior and independent living units, with a heavy tilt toward high‑growth markets such as Texas that could fuel future earnings.
High Clinical Quality and Outcomes
Management put significant emphasis on clinical metrics, arguing that quality underpins both pricing power and occupancy. Same‑store facilities outperformed peers in annual surveys and 5‑star quality measures, with about 85% of operations rated 4 or 5 stars, which should strengthen Ensign’s position with payors and referral partners.
Turnaround Facilities Driving Incremental Growth
The call spotlighted facility‑level turnarounds as proof of the operating model, with properties like Sun West in Phoenix and Mystic Park in San Antonio posting sharp jumps in revenue and earnings. These turnarounds also posted large gains in skilled mix and quality ratings, illustrating how Ensign can create value from underperforming assets over time.
Strong Balance Sheet and Ample Liquidity
Ensign underscored its financial flexibility, pointing to $539.5 million of cash and $100.2 million in operating cash flow generated in the quarter. With more than $1 billion in total available capital and lease‑adjusted net debt‑to‑EBITDA at 1.73x, the company appears well‑positioned to keep investing aggressively without overstretching its balance sheet.
Standard Bearer REIT Performance
The company’s affiliated REIT, Standard Bearer, continues to scale as a strategic real estate platform, generating $36.1 million in rental revenue and $21.6 million in FFO in the quarter. It now owns 173 properties and is diversifying its tenant base with 37 third‑party leases, while maintaining healthy EBITDAR‑to‑rent coverage of 2.7x.
Labor, Turnover and Retention Improvements
On the cost side, Ensign reported progress in labor management, historically a pain point for the sector. A reduced reliance on agency staffing, improving overtime metrics and a 32% decline in director‑of‑nursing turnover over two years suggest better operational stability and potential margin support in future quarters.
Industry Review and Reimbursement Scrutiny
Management acknowledged heightened industry‑wide clinical reviews and tighter managed care scrutiny as an ongoing risk to reimbursement and claims. However, they noted that, so far, Ensign has not seen a material system‑wide impact, framing the issue more as a source of potential volatility than a current earnings headwind.
Near‑Term EPS Drag from Turnaround Deals
Investors were reminded that some recent acquisitions are expected to lift revenue faster than EPS as Ensign invests to reposition the facilities. Management stressed that these are strategic, higher‑quality assets that should eventually deliver strong returns, but near‑term profit contribution may lag headline top‑line growth.
ERP System Implementation Friction
A new enterprise resource planning system went live at the start of the year, and leadership cautioned about transitional inefficiencies during the early phase. While the system is expected to enhance data, reporting and operational control over the long term, it may temporarily add extra work and small friction points for field operators.
Seasonality and Short‑Term Headwinds
The company also flagged normal seasonal softness in skilled mix and higher relative costs in the summer quarters, which could affect sequential trends. In addition, variability in state reimbursement timing, staffing, and the integration of new acquisitions may create lumpiness, even as the broader trajectory remains positive.
State Medicaid Budget Uncertainty
Ensign characterized the current Medicaid environment as generally stable but put some states on a watch list given emerging budget strains. Management emphasized ongoing engagement with state officials, but investors were reminded that medium‑term policy shifts in key markets could still influence revenue and margin trajectories.
Premium‑Priced Strategic Acquisitions
The company has also paid higher prices for newer, high‑quality facilities in select strategic markets, a move it believes will pay off over a longer horizon. These premium deals can extend the typical timeline for realizing target returns, adding some execution and timing risk to the growth algorithm even as they enhance the portfolio’s overall quality.
Forward‑Looking Guidance and Outlook
Looking ahead, the raised 2026 guidance is anchored by robust Q1 execution, strong liquidity and a deep pipeline of acquisitions already closed or expected by midyear. Assumptions include stable tax and share counts and alignment with a modest proposed government rate increase, painting a picture of continued double‑digit earnings growth if operational momentum holds.
Ensign’s earnings call painted a picture of a company executing well on multiple fronts, from occupancy and mix to M&A and clinical quality, while using a conservative balance sheet to support growth. For investors, the story is one of strong current fundamentals with clearly spelled‑out risks that appear manageable, supporting confidence in its multi‑year growth profile.